Introduction
The carcinoid syndrome is characterised by flushing, diarrhoea, heart disease, and wheezing and in most cases is associated with extensive metastases from a malignant gastrointestinal tumour.1 In general these tumours are of low grade malignancy, and survival of up to 20 years despite symptoms has been reported.2 Nevertheless, the range of the disease is wide, and other series have shown a much shorter mean survival time. In one series of patients with carcinoid tumours and proved metastases mean survival was only months.3 By the time the syndrome is present the tumours have produced extensive metastases, and therefore traditional modes of management include pharmacological modification of the symptoms, limited surgical procedures to reduce tumour bulk or devascularise hepatic metastases, and cytotoxic treatment. Each of these approaches has its limitations and hazards, and all have proved disappointing. 4 Allison et al from this institution reported that in two patients with the carcinoid syndrome and extensive metastases the symptoms initially responded dramatically to hepatic arterial embolisation. 5 We describe our experience with this therapeutic approach over the past six years and give the long term results, benefits, and potential hazards.
Patients and methods

PATIENTS
Eighteen patients (12 men, six women; aged 38-76) with the carcinoid syndrome have been considered for hepatic arterial embolisation in the past six years. All had had symptoms of the syndrome for at least six months, the range being six months to eight years. All 18 patients had noticed episodic or continuous flushing, 13 had had diarrhoea, 13 peripheral oedema, 12 signs of carcinoid heart disease, seven abdominal pain, four wheezing, and five a pellagroid rash.
All patients were admitted for assessment to establish the severity of the symptoms and define the extent of metastatic spread of the tumour. This included clinical assessment of symptoms, use of various imaging techniques to define tumour deposits, and measurement of 24 hour urinary excretion of 5-hydroxyindole acetic acid. One patient suffered only from mild flushing precipitated by drinking alcohol or exercise. She was treated by dietary advice alone and was followed up in the outpatients clinic; her symptoms had not progressed two years later. Four patients were not considered for embolisation because of advanced disease, and indeed three of these died during their first admission to our unit. We therefore selected 13 patients for embolisation in whom symptoms were severe and had become resistant to pharmacological agents.
were stopped after four to five days. Initially, we continued antibiotics for five days, but later we continued them for 10 days or for longer if fever persisted.
Results
Twelve of the 13 patients who proceeded to angiography underwent embolisation: in one patient the coeliac axis injection showed an occluded portal vein, which is a contraindication to embolisation. Embolisation was unsatisfactory in two further patients. In one the hepatic artery had been previously ligated, which prevented adequate embolisation, and the other was severely ill (see below).
Early complications of embolisation-One of the 12 patients who underwent embolisation died from a cardiac arrest within a few hours after the procedure. She had been moribund before the procedure with cachexia, heart failure, and massive hepatomegaly. She was one of the early patients in this series, and subsequently embolisation was not performed in such severely ill patients. Another patient who had initially responded to the procedure died eight days 
METHODS
Before the procedure each patient began a regimen designed to prevent complications arising from release of tumour metabolites. Forty eight hours before embolisation cyproheptadine (a serotonin blocker) 4 mg thrice daily by mouth and fenclonine (an inhibitor of s.ynthesis of serotonin) 4 mg thrice daily by mouth were started. A central venous line was inserted. On the day of embolisation the patient was premedicated with papaveretum and scopolamine, and cloxacillin 500 mg four times intravenously or by mouth, tobramycin 80 mg thrice daily intravenously or intramuscularly, and metronidazole 500 mg four times daily intravenously or by mouth were started. Just before the procedure methylprednisolone 1 g was administered and an aprotinin infusion of 50 000 IU/h started. Within the angiographic suite human plasma protein fraction was available in case hypotension occurred and hydralazine (10-15 mg intravenously) for hypertension.
The femoral artery was cannulated under local anaesthesia, the coeliac axis entered, and contrast medium injected. The arterial phase was studied to define the extent of the hepatic metastases, and the venous phase to determine the degree of patency of the portal vein-an essential preliminary step. If the portal vein was patent then the hepatic artery or its branches were selectively catheterised and the tumour vasculature embolised. Initially small pieces (1-3 mm) of slowly absorbed gelatin sponge (Sterispon, Allen and Hanbury's) was used to embolise the vessels, but subsequently a mixture of Sterispon and human dura mata (Lyodura, Davis and Gear) in 250' dextrose, tobramycin, and contrast medium was used, and steel coils were inserted in segmental arteries. A further angiographic study was performed to check that the embolisation was satisfactory.
After embolisation pulse and blood pressure were monitored closely for 24 hours, pethidine was given as required for analgesia, and aprotinin was continued for 48 hours. necrotic tumour, and then fell to below the valu embolisation. This pattern of response was found i whom embolisation was successful.
Early effects of embolisation on symptoms and signslived for at least five days after embolisation noted eit reduction or complete abolition of their symptoms af Flushing was abolished in all eight patients in who major symptom, and abdominal pain was relieved in in whom it had been troublesome. In the two patie embolisation produced complete symptom relief. in the five patients who had had diarrhoea before from 10 5 (SD 7 6) stools/day before embolisation tc day after embolisation. This difference is more in appears because before embolisation these patients symptomatic treatment including codeine, loperan mine, and methysergide and after embolisation tl were reduced or stopped. In keeping with the clir improvement urinary secretion of 5-hydroxyindole from 1048 (716) Two patients with recurrent symptoms were assessed for a second embolisation and had further remissic for up to six months. Subsequent embolisation in one however, had no beneficial effect. Five of the eigh one, who had been symptom free, died of an unri month after embolisation, and the others, all with recu died of advanced carcinoid disease. All these patient in sites other than the liver, such as the bones, skin three had severe heart disease, as well as flushing In those patients who died the mean survival after e 1 6 (1 2) years. Survival time from the first symptom was 4 2 (3-2) years, compared with 2 9 (1 7) year whom embolisation was not performed.
Discussion
The main objective of hepatic embolisation wsevere intractable symptoms of the carcinoid each case flushing, diarrhoea, or hepatic paii intolerable despite high doses of blocking agent In all patients who could be adequately assessec did indeed relieve symptoms, and these remiss up to 18 months. That this response was due tumour mass was evidenced by the variables of the time of embolisation and the subsequent excretion of 5-hydroxyindole acetic acid and imaging tests. Embolisation would seem to offer appreciable advantages over surgery and chemotherapy in advanced cases of the carcinoid syndrome. Surgery in these patients has a high mortality, and anaesthetic problems are considerable. 6 Furthermore, the morbidity associated with any surgery, even hepatic artery ligation,' in patients with advanced carcinoma and a limited prognosis is considerable, and ligation as a method of devascularisation does not seem to be effective as an extensive anastomotic circulation rapidly develops.8 This is not seen with embolisation because the technique occludes the small vessels as well as the large ones, preventing establishment of a collateral supply.5 Results of cytotoxic treatment in the carcinoid syndrome have been disappointing, whether single or multiple agents have been used.4 8 Although some reduction in liver size has been documented, symptomatic response has been poor, and indeed symptoms may be exacerbated, presumably because of tumour necrosis. longed course of broad spectrum antibiotics after embolisation until fever disappears is emphasised by the fact that the major complications of embolisation in this series were due to infection : -Z ;::: 7/7 40 of necrotic liver tissue. Although in one of the cases in this series the presence of gas in the liver was associated with a hepatic abscess, this is not always so. Parenchymal gas may be demonstrated in the embolised liver in one third of all patients in whom embolisation has been performed but is only 1_____ occasionally associated with infection. 9 The survival time of patients in this series was not long. All these patients, however, had had severe symptoms for 30 months or years, and many also had carcinoid heart disease or metastases beyond the liver, or both. These factors limit the e f and survival in survival of patients, no matter how successful the hepatic embolisation. It is therefore not clear from our data whether hepatic embolisation increases (or even decreases) life expectancy. In addition, the optimal selection policy for embolisation was periods. This current practice should be associated with much lower mortality, and morbidity should be limited to minor complications such as pain or hypertension. As the cystic artery is a branch of the hepatic, however, necrosis of the gall bladder remains a risk of hepatic embolisation. as to relieve the It is not clear at present which patients will benefit most from 
